News & Events:

Despite adoption of molecular biomarkers in the management of non-small cell lung cancer (NSCLC), the recently adopted 8th Edition staging utilized only clinicopathologic characteristics, and validated improvement in risk stratification of early-stage disease remains elusive. We therefore evaluated the integration of a clinically-validated molecular prognostic classifier into conventional staging.... Incorporation of a molecular prognostic classifier significantly improved identification of high-risk patients and survival predictions compared to conventional staging. TNMB may lead to [...]

A team led by Bhairavi Tolani, Ph.D. and David M. Jablons, M.D. has developed and characterized a potential novel therapeutic for Sonic hedgehog (Shh)-driven cancers, including some lung cancers. Dr. Tolani is an assistant professor and member of the Thoracic Oncology Program, and principal investigator in the Tolani Laboratory. Dr. Jablons is director of the Thoracic Oncology Program and Thoracic Oncology Lab.  The researchers reported last October that full-length Shh protein present on the cell membrane identified cells with cancer stem cell (CSC) features implicated in NSCLC. To target [...]

Building on earlier retrospective validation studies, a team of Thoracic Oncology Program researchers, demonstrated in a small prospective study the clinical utility of a 14-gene expression assay in stratifying risk among non-small cell lung cancer (NSCLC) patients. In a recently published paper in the journal Clinical Lung Cancer, lead author Gavitt Woodard, M.D., a general surgery research resident in the Thoracic Oncology Laboratory, and coauthors  David M. Jablons, M.D. (pictured second) and Michael Mann, M.D., (pictured 3rd) began  to address a key question regarding widespread use of [...]